Epizootic hemorrhagic disease virus - tel aviv university (ehdv-tau) - oncolytic virus for treating cancer
AssigneeRamot at Tel-Aviv University Ltd.
InventorsMarcelo EHRLICH, Eran BACHARACH, Ben SHAI, Oded DANZIGER
Life of this patent
Estimating the term…
Abstract
The present invention relates to a unique oncolytic virus, Epizootic Hemorrhagic Disease virus-Tel Aviv University (EHDV-TAU), and to methods and pharmaceutical compositions comprising thereof for preventing or treating cancer exhibiting an alteration in interferon signaling and/or the innate immune antiviral response.
Claims20
A method for preventing or treating cancer exhibiting an alteration in interferon signaling and/or the innate immune antiviral response, comprising administering an oncolytic Epizootic Hemorrhagic Disease virus-Tel Aviv University (EHDV-TAU) virus, or a pharmaceutical composition comprising thereof, to a subject.
An oncolytic EHDV-TAU virus for preventing or treating cancer exhibiting an alteration in interferon signaling and/or the innate immune antiviral response.
A process for the preparation of a cancer-specific oncolytic virus, comprising infecting human cells with Epizootic Hemorrhagic Disease Virus 2-Ibaraki (EHDV2-Ibaraki), to obtain a cell adapted EHDV2-Ibaraki (EHDV2-IBA) and further modifying EHDV2-IBA to target the specific cancer by a chemical modification, site-directed mutagenesis, in-vitro evolution or any combination thereof.
Dependencies are inferred from the claim text.